STAT

Opinion: For medicine regulators, reliance is a global imperative

A new report from the U.S. National Academies, "Regulating Medicines in a Globalized World," shows how regulatory authorities can work together and avoid duplication.

It’s never been more challenging to make sure that medicines meet standards for quality, safety, and effectiveness. Rapidly evolving technologies, advances in medical therapies, and increasingly complex supply chains are stressing medicine regulators around the globe.

Great gains can be made when countries’ medicine regulators work together and share resources to ensure that their citizens have timely access to high-quality, safe, and effective medicines — an important role of government and an essential public health function.

Regulatory authorities that share information or that rely on each other’s work have expedited the approval of essential vaccines and medicines, prevented the distribution of substandard and fake medicines, and

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About BIO’s China Challenge, Zepbound Shortages, And More
BIO's about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and forcefully.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks